BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li D, Huang Z, Zhong J. Hepatitis C virus vaccine development: old challenges and new opportunities. National Science Review 2015;2:285-95. [DOI: 10.1093/nsr/nwv040] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Anticoli S, Falcone E, Ruggieri A, Federico M. Engineered exosomes boost the HCV NS3-specific CD8+ T lymphocyte immunity in humans. Trials in Vaccinology 2016;5:105-10. [DOI: 10.1016/j.trivac.2016.05.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
2 Jadoul M, Bieber BA, Martin P, Akiba T, Nwankwo C, Arduino JM, Goodkin DA, Pisoni RL. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int 2019;95:939-47. [PMID: 30904068 DOI: 10.1016/j.kint.2018.11.038] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 18.0] [Reference Citation Analysis]
3 Atapour A, Mokarram P, Mostafavipour Z, Hosseini SY, Ghasemi Y, Mohammadi S, Nezafat N. Designing a Fusion Protein Vaccine Against HCV: An In Silico Approach. Int J Pept Res Ther 2019;25:861-72. [DOI: 10.1007/s10989-018-9735-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
4 Wang X, Yan Y, Gan T, Yang X, Li D, Zhou D, Sun Q, Huang Z, Zhong J. A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey. Gut 2019;68:140-9. [PMID: 29180585 DOI: 10.1136/gutjnl-2017-314870] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
5 Saab S, Le L, Saggi S, Sundaram V, Tong MJ. Toward the elimination of hepatitis C in the United States. Hepatology 2018;67:2449-59. [PMID: 29181853 DOI: 10.1002/hep.29685] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
6 Pouriayevali MH, Bamdad T, Sadat SM, Sadeghi SA, Sabahi F, Mahdavi M, Aghasadeghi MR. Listeriolysin O immunogenetic adjuvant enhanced potency of hepatitis C virus NS3 DNA vaccine. IUBMB Life 2019;71:1645-52. [PMID: 31298809 DOI: 10.1002/iub.2109] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
7 Tao W, Gan T, Lu J, Zhong J. A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals. Antiviral Res 2017;139:18-24. [PMID: 28025084 DOI: 10.1016/j.antiviral.2016.12.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
8 Leumi S, Guo M, Lu J, Wang Z, Gan T, Han L, Ngari J, Tong Y, Xiang X, Xie Q, Wang L, Zhong J. Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance. Antiviral Res 2021;197:105224. [PMID: 34864126 DOI: 10.1016/j.antiviral.2021.105224] [Reference Citation Analysis]